Gut help to prevent diarrhea from EGFR-targeted lung cancer drugs
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 trial tests whether adding glutamine plus L. reuteri can help prevent severe diarrhea caused by EGFR-targeted treatments in people with advanced non-small cell lung cancer. If it works, it could make treatment easier to tolerate and help you stay on the planned therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to consent
- Have non-small cell lung cancer confirmed by biopsy/pathology
- Have stage IIIB, IIIC, or IV (advanced disease)
- Be starting an EGFR-targeted pill treatment (1st or 2nd generation), like an EGFR TKI
- Be well enough for study participation (ECOG 0–2) and expected to live more than 8 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
This trial tests if adding a probiotic (Lactobacillus rhamnosus M9) to standard radiation and immunotherapy can help people with advanced digestive system cancers. It aims to see if the combination is more effective and safer than the standard approach alone.
This trial tests whether the bacteria in your gut (microbiome) can affect how well immunotherapy works for lung cancer that can be surgically removed. You may receive immunotherapy or chemotherapy before surgery to shrink the tumor.
This study looks at how your gut bacteria might affect a treatment for lung cancer that combines chemotherapy and immunotherapy before surgery. It aims to see if certain bacteria can help the treatment work better.
This study tests whether a probiotic supplement (LR607) can help patients with newly diagnosed non-small cell lung cancer—a common type of lung cancer. Probiotics are beneficial bacteria that may help your immune system fight cancer alongside standard treatments.
This trial tests whether adding a probiotic (Lactobacillus Johnsonii) to standard chemotherapy and immunotherapy can help people with certain advanced solid tumors that have stopped responding to prior immunotherapy. It may help your immune system work better against the cancer.
Hear when a new Non-Small Cell Lung Cancer With EGFR Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.